Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Kimberly-Clark (KMB) stock in plain English

Free brief · no signupStart here
KMBPublished Nov 13, 2026
Kimberly-Clark Corp
Consumer Defensive · Household & Personal Products
Sells diapers, facial tissues, feminine pads, and over-the-counter medications to consumers and hospitals worldwide.
Assets:
Global manufacturing networkOperates dozens of mills and plants across North America, Latin America, Europe, and Asia
Flagship diaper businessProduces Huggies diapers and Pull-Ups training pants in dedicated automated facilities
Kenvue healthcare portfolioControls major over-the-counter drug lines including Tylenol, Motrin, and Zyrtec
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

55
OPS ScoreOperating finances
Latest quote
-1.86%$105.25
$64.59B
10.6×
$16.56B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was KMB. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Kimberly-Clark (KMB) do?

Kimberly-Clark Corp (KMB) is a U.S.-listed company in Consumer Defensive (Household & Personal Products). What it does: Sells diapers, facial tissues, feminine pads, and over-the-counter medications to consumers and hospitals worldwide. It manufactures paper-based hygiene products and over-the-counter healthcare items distributed through major global. It is worth $64.59B on the market and sold $16.56B over the last year.

Market cap
$64.59B
P/E ratio
10.6×
Annual sales
$16.56B
Sector
Consumer Defensive
Industry
Household & Personal Products
Brief updated
Nov 13, 2026

Brands and businesses behind KMB

  • Huggies: Sells disposable baby diapers and baby wipes to mass retailers, earning revenue per unit sold.
  • Tylenol: Sells acetaminophen pain relief medication to retail pharmacies and supermarkets, earning wholesale revenue per package.
  • Kleenex: Sells facial tissues to consumers and commercial facilities through wholesale retail supply contracts.
  • Kotex: Sells feminine hygiene products including pads and tampons to retail chains across international markets.
  • Listerine: Sells antiseptic mouthwash and oral rinse products to grocery stores and pharmacies.
  • Neutrogena: Sells skincare, sun care, and cosmetic items through department stores and drugstores globally.

KMB’s flags, in plain English

Each flag is a number from Kimberly-Clark’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Capital Works Hard

Earns 37.5% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.

Pays You to Hold

Pays a 4.87% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.

Bargain or Trap?

Priced at 10.6 times its yearly profit, on the cheap side. The stock trades cheaper than it usually does. A low price can hide a real problem, so read the risks.

Profit with Caveats

Bottom-line profit of $3.3B in the 12 months to Sep 30, 2026, next to $2.4B of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about KMB

How big is Kimberly-Clark?

Kimberly-Clark’s market cap is $64.59B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $16.56B: what customers paid the company over the last year, before any costs.

What is KMB’s P/E ratio?

KMB’s P/E ratio is 10.6×. Investors pay about 10.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with KMB?

Debt servicing costs have risen sharply following the multi-billion dollar acquisition of Kenvue. That is one risk on Kimberly-Clark’s card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Kimberly-Clark’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KMB’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card